- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified ...
BBP-418 was generally well tolerated, with a safety profile comparable to placebo. Treatment-emergent adverse events (TEAEs) were reported in 93.2% of individuals receiving BBP-418 and 100% of ...
Detailed price information for Mbx Biosciences Inc (MBX-Q) from The Globe and Mail including charting and trades.
Barclays 28th Annual Global Healthcare Conference March 11, 2026 12:30 PM EDTCompany ParticipantsNeil Kumar - Co-Founder, ...
The shortage of commercial LPG cylinders triggered disruptions across restaurants, hostels, canteens and catering services in multiple cities, highlighting the vulnerability of India’s food service ...
Earnings call BKW AG reported CHF 4.5 billion in operating income for 2025, down 4.8% YoY, with EBIT at CHF 113.7 million (-14.6%) and net profit declining 19.3%. Despite lower hydro output and market ...
Khan, S. and Issa, H. (2026) Uncontrolled Hypothyroidism with Antiphospholipid Syndrome Resulting in Myxedema Psychosis. Open Journal of Psychiatry, 16, 131-138. doi: 10.4236/ojpsych.2026.162010 .
Some results have been hidden because they may be inaccessible to you
Show inaccessible results